Conventional chemotherapy lacking target selectivity often leads to severe side effects,
limiting the effectiveness of chemotherapy. Therefore, drug delivery systems ensuring both …

Peptide therapy has started since 1920s with the advent of insulin application, and now it
has emerged as a new approach in treatment of diseases including cancer. Using anti …

Peptide‒drug conjugates (PDCs) are drug delivery systems consisting of a drug covalently
coupled to a multifunctional peptide via a cleavable linker. As an emerging prodrug strategy …

Nanoparticles (NPs) are atomic clusters of crystalline or amorphous structure that possess
unique physical and chemical properties associated with a size range of between 1 and 100 …

Background Despite tremendous advancements in cancer treatment delivery, we are still far
from achieving successful cancer prognosis and cure. The use of new nanocarriers for site …

Peptide-drug conjugates (PDCs) are a class of novel molecules widely designed and
synthesized for delivering payload drugs. The peptide part plays a vital role in the whole …

Peptide-drug conjugates (PDCs) are gaining considerable attention as anti-neoplastic
agents. However, their development is often laborious and time-consuming. Herein, we …

The obstruction of blood–brain barrier (BBB) and the poor specific targeting are still the
major obstacles and challenges of targeted nano-pharmaceutical therapy for glioblastoma …

This study is a continuation of an investigation into the effect of a targeted component, a
peptide with an NGR, on the properties of the previously developed doxorubicin …

Abstract The usage of Peptide-Based Drug-delivery systems (PBDs) is a strategy in which
peptides carry a variety of compounds with pharmacological activity into cells. These …